BioVie Inc. Warrant closed at $0.28 on Sep 28, down 6.67%, 49.1% below its highest close since Aug 8. Volume of 22.5K shares was 0.35× its 20-day average (below normal).
Split-adjusted performance: -20.0% over one month, +7.7% over six months.
Short interest was 43.3K shares at the Sep 15 settlement, down 90.7% from the prior report (1.0 days to cover).
No reported quarters with price history yet.
Percentile among 423 companies (100 = best)
Industry medians: 6-month return −2.9%, revenue growth +6.4%, net margin −41.2%, P/E 16.2×.
No recent articles focused on BioVie Inc. Warrant.
BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
